Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

NCT03269695 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class

Stopped The Sponsor changed R\&D strategy and priority.

Conditions

Interventions

Sponsor

Pfizer